Inhibition of protein kinase C delta leads to cellular senescence to induce anti-tumor effects in colorectal cancer.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Jun 2023
Historique:
revised: 10 02 2023
received: 17 10 2022
accepted: 21 02 2023
medline: 5 6 2023
pubmed: 1 3 2023
entrez: 28 2 2023
Statut: ppublish

Résumé

Protein kinase C delta (PKCδ) is a multifunctional serine-threonine kinase implicated in cell proliferation, differentiation, tumorigenesis, and therapeutic resistance. However, the molecular mechanism of PKCδ in colorectal cancer (CRC) remains unclear. In this study, we showed that PKCδ acts as a negative regulator of cellular senescence in p53 wild-type (wt-p53) CRC. Immunohistochemical analysis revealed that PKCδ levels in human CRC tissues were higher than those in the surrounding normal tissues. Deletion studies have shown that cell proliferation and tumorigenesis in wt-p53 CRC is sensitive to PKCδ expression. We found that PKCδ activates p21 via a p53-independent pathway and that PKCδ-kinase activity is essential for p21 activity. In addition, both repression of PKCδ expression and inhibition of PKCδ activity induced cellular senescence-like phenotypes, including increased senescence-associated β-galactosidase (SA-β-gal) staining, low LaminB1 expression, large nucleus size, and senescence-associated secretory phenotype (SASP) detection. Finally, a kinase inhibitor of PKCδ suppressed senescence-dependent tumorigenicity in a dose-dependent manner. These results offer a mechanistic insight into CRC survival and tumorigenesis. In addition, a novel therapeutic strategy for wt-p53 CRC is proposed.

Identifiants

pubmed: 36851883
doi: 10.1111/cas.15768
pmc: PMC10236638
doi:

Substances chimiques

Protein Kinase C-delta EC 2.7.11.13
Tumor Suppressor Protein p53 0
Cyclin-Dependent Kinase Inhibitor p21 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2471-2484

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP16K18434
Organisme : Japan Society for the Promotion of Science
ID : JP17H03584
Organisme : Japan Society for the Promotion of Science
ID : JP18K15253
Organisme : Japan Society for the Promotion of Science
ID : JP18K19484
Organisme : Japan Society for the Promotion of Science
ID : JP20H03519
Organisme : Japan Society for the Promotion of Science
ID : JP20K07621

Informations de copyright

© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Eur J Med Chem. 2018 Jan 20;144:582-594
pubmed: 29289883
Nat Commun. 2021 Aug 17;12(1):4841
pubmed: 34404770
Pharmacol Res. 2016 Jan;103:26-48
pubmed: 26529477
Cancer Sci. 2023 Jun;114(6):2471-2484
pubmed: 36851883
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
J Biol Chem. 2005 Oct 7;280(40):33926-34
pubmed: 16055435
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Nat Cell Biol. 2020 Aug;22(8):960-972
pubmed: 32719551
Annu Rev Physiol. 2013;75:685-705
pubmed: 23140366
Cancer Cell. 2018 Dec 10;34(6):954-969.e4
pubmed: 30537515
Int J Oncol. 1999 Sep;15(3):491-8
pubmed: 10427130
Nat Rev Mol Cell Biol. 2014 Jul;15(7):482-96
pubmed: 24954210
Cancer Res. 2013 Oct 15;73(20):6099-105
pubmed: 24097826
Science. 2001 Feb 2;291(5505):868-71
pubmed: 11157165
Cancer Res. 2021 Jan 15;81(2):414-425
pubmed: 33318039
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Carcinogenesis. 2011 May;32(5):676-85
pubmed: 21310943
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
Oncogene. 2002 Sep 12;21(41):6328-39
pubmed: 12214273
Biochem Mol Biol Int. 1998 Mar;44(3):523-8
pubmed: 9556213
Gastroenterology. 1994 Jan;106(1):42-8
pubmed: 8276207
Oncogene. 2014 Mar 6;33(10):1306-15
pubmed: 23474764
BMB Rep. 2019 Jan;52(1):42-46
pubmed: 30526772
Drug Discov Today. 2016 Jan;21(1):5-10
pubmed: 26210956
Apoptosis. 2007 Jul;12(7):1339-47
pubmed: 17431791
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Chem Rev. 2001 Aug;101(8):2209-42
pubmed: 11749371
EMBO J. 2015 Jun 3;34(11):1493-508
pubmed: 25736378
Nat Cell Biol. 2001 Mar;3(3):245-52
pubmed: 11231573
J Surg Res. 1995 Feb;58(2):233-9
pubmed: 7861778
Int J Cancer. 2005 Jan 1;113(1):42-53
pubmed: 15386430
Mol Cell Biol. 2007 Dec;27(24):8480-91
pubmed: 17938203
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Trends Cell Biol. 2012 Apr;22(4):211-9
pubmed: 22245068
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Clin Cancer Res. 2013 Sep 15;19(18):4961-71
pubmed: 23881925
Front Biosci (Landmark Ed). 2009 Jan 01;14(6):2386-99
pubmed: 19273207
Clin Chim Acta. 2007 Jul;382(1-2):54-8
pubmed: 17459358
J Biol Chem. 2006 Mar 3;281(9):5734-40
pubmed: 16377624
J Med Chem. 2013 Mar 14;56(5):1799-810
pubmed: 23398373
Trends Pharmacol Sci. 2014 Nov;35(11):604-20
pubmed: 25312588
BMB Rep. 2019 Jan;52(1):35-41
pubmed: 30526771
Br J Cancer. 2008 Nov 18;99(10):1644-50
pubmed: 19002183
Mol Cell Biol. 2001 Jun;21(12):4016-31
pubmed: 11359909
FEBS Lett. 2002 Nov 6;531(2):319-23
pubmed: 12417334
Nat Cell Biol. 2002 May;4(5):E127-30
pubmed: 11988757
J Med Chem. 2022 Jan 27;65(2):1329-1341
pubmed: 34191518

Auteurs

Yuya Shimoyama (Y)

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan.

Kohji Yamada (K)

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan.

Saishu Yoshida (S)

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan.

Akira Kawamura (A)

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan.

Yoshito Hannya (Y)

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan.

Yuta Imaizumi (Y)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Tomotaka Kumamoto (T)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Yasuhiro Takeda (Y)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Masayuki Shimoda (M)

Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan.

Ken Eto (K)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Kiyotsugu Yoshida (K)

Department of Biochemistry, The Jikei University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH